Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06762925

Enrollment

450

Registered

2025-01-08

Start date

2025-01-30

Completion date

2026-06-01

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer, Kidney Cancer, Prostate Cancer

Brief summary

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Interventions

OTHERNo Interventions

No Interventions

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Patients diagnosed with urinary system tumors through pathological examination; 2. Meet specific clinical stages and surgical treatment standards; 3. Intraoperative tissue resection meets the sample testing standards; 4. The patient is willing to participate in the study and sign an informed consent form.

Exclusion criteria

1. Not meeting the specific clinical stage and not receiving surgical treatment; 2. Abnormal mental behavior; 3. Intellectual disability; 4. Age under 18 years old or over 75 years old; 5. Low understanding and communication skills.

Design outcomes

Primary

Measure	Time frame
The expression levels of METTL3 and ANGPTL2	About a year and a half

Contacts

Primary Contactshihao shang

shang225@hotmail.com17868780610

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026